Clinical Trial Update: Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) [Phase 2]

View source ↗

Summary

Phase 2 trial ASPRIA is evaluating atezolizumab plus sacituzumab govitecan to prevent recurrence in triple-negative breast cancer, including patients with resid…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: RECRUITING